Creo Medical Announces First Patient Treated with Speedboat

Progression of first commercial product on track

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, is pleased to announce the first clinical use of the Company’s Speedboat device.

The first patient with a large pre-cancerous lesion in the gastrointestinal (GI) tract was treated using Creo’s Speedboat device powered by Creo’s CROMA electrosurgery advanced energy platform. The patient was treated by Professor Brian Saunders at St. Mark’s Hospital in London, United Kingdom.

Craig Gulliford, Chief Executive Officer of Creo Medical, commented:

The first treatment of a patient is a significant inflection in the commercialisation of our first product from the endoscopic pipeline. In-line with our strategy, we are increasing surgeon training to expand clinical awareness and bring the benefits of this important new development to those patients in need. We have a complementary range of products in development and believe that this positions Creo well to become a leader in this growing billion dollar market. We look forward to treating more patients in the near future and sharing our experience with the wider clinical community.

The Speedboat device harnesses the precise cut and coagulation capability of CROMA to remove early cancerous and pre-cancerous lesions in the bowel. The use of the Speedboat device helps reduce the risks associated with alternative laparoscopic procedures, reducing the length of hospital stays and transferring therapy from the operating room to the endoscopy room

Endoscopy has been a rapidly expanding practice due to the advent of colorectal cancer screening in most healthcare systems. This has driven growth in equipment and devices to enhance the ability to screen, detect and treat early stage and pre-cancerous lesions in the GI tract.

Posted 17/06/2017

For press enquiries please contact For all other enquiries please visit our Contact page.

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)


13 May 2024

Directorate Changes - May 2024


07 May 2024

Creo Medical receives King’s Award for Enterprise in Innovation


02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital


24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings


19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch